Ono Pharmaceutical Co., Ltd. (OPHLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ono Pharmaceutical Co., Ltd. (OPHLF) with AI Score 59/100 (Hold). Ono Pharmaceutical Co. , Ltd. is a Japanese pharmaceutical company focused on the development, manufacturing, and marketing of innovative drugs. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Ono Pharmaceutical Co., Ltd. (OPHLF) Healthcare & Pipeline Overview
Ono Pharmaceutical Co., Ltd., established in 1717, develops and markets pharmaceutical products and diagnostic reagents globally. With a diverse portfolio spanning oncology, diabetes, and immunology, the company maintains a strong presence in the healthcare sector, supported by collaborations and a robust pipeline, and currently has a market capitalization of $6.58 billion.
Investment Thesis
Ono Pharmaceutical presents a compelling investment case based on its established market presence, diverse product portfolio, and strategic collaborations. With a P/E ratio of 17.79 and a profit margin of 12.3%, the company demonstrates financial stability. Growth catalysts include the expansion of existing product lines like Opdivo and Forxiga, as well as the development of new therapies in its pipeline. The company's dividend yield of 3.39% offers an attractive return for investors. However, potential risks include regulatory hurdles, competition from other pharmaceutical companies, and the inherent uncertainties of drug development. The company's beta of 0.10 suggests low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $6.58 billion indicates substantial company size and investor confidence.
- P/E ratio of 17.79 suggests a reasonable valuation compared to earnings.
- Profit margin of 12.3% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 69.8% reflects efficient cost management in the production and sales of pharmaceuticals.
- Dividend yield of 3.39% provides a steady income stream for investors.
Competitors & Peers
Strengths
- Innovative drug pipeline
- Strong market position in Japan
- Strategic collaborations with leading research institutions
- Diverse product portfolio
Weaknesses
- Reliance on a few key products
- Limited presence in some emerging markets
- Exposure to generic competition
- OTC listing may limit access to capital
Catalysts
- Upcoming: Clinical trial results for novel therapies in the pipeline.
- Upcoming: Regulatory approvals for new indications of existing drugs.
- Ongoing: Expansion of strategic collaborations and partnerships.
- Ongoing: Increasing demand for pharmaceutical products in emerging markets.
- Ongoing: Development of digital health solutions to improve patient outcomes.
Risks
- Potential: Regulatory changes and pricing pressures could impact revenue.
- Potential: Competition from other pharmaceutical companies could erode market share.
- Potential: Patent expirations could lead to generic competition.
- Ongoing: The inherent uncertainties of drug development could result in clinical trial failures.
- Ongoing: Economic downturns could reduce demand for pharmaceutical products.
Growth Opportunities
- Expansion of Opdivo's Indications: Ono Pharmaceutical has the opportunity to expand the approved indications for Opdivo, its leading oncology drug. This includes pursuing approvals for new cancer types and combination therapies. The global oncology market is projected to reach $286.6 billion by 2031, providing a substantial market for Opdivo's continued growth. Timeline: Ongoing clinical trials and regulatory submissions.
- Development of Novel Therapies: Ono Pharmaceutical's pipeline includes several promising drug candidates targeting various diseases, including autoimmune disorders, neurological conditions, and other cancers. Successful development and commercialization of these therapies could significantly boost revenue. The market for autoimmune disease treatments is expected to reach $150 billion by 2028. Timeline: Clinical trials in progress with potential launches in the next 3-5 years.
- Strategic Collaborations and Acquisitions: Ono Pharmaceutical can pursue strategic collaborations and acquisitions to expand its product portfolio and geographic reach. Partnering with biotech companies and research institutions can accelerate drug development and access new technologies. The company's existing collaborations with Adimab LLC and Turbine Ltd. demonstrate its commitment to this strategy. Timeline: Ongoing, with potential deals announced in the next 1-2 years.
- Geographic Expansion: Ono Pharmaceutical can expand its presence in emerging markets, such as China and India, where there is a growing demand for pharmaceutical products. This includes establishing local manufacturing facilities and distribution networks. The pharmaceutical market in emerging economies is expected to grow at a faster rate than developed markets. Timeline: Gradual expansion over the next 5-10 years.
- Digital Health Integration: Ono Pharmaceutical can leverage digital health technologies, such as telemedicine and mobile health apps, to improve patient outcomes and enhance its market reach. This includes developing digital therapeutics and remote monitoring solutions. The digital health market is projected to reach $660 billion by 2028. Timeline: Pilot programs and partnerships in the next 2-3 years, followed by broader implementation.
Opportunities
- Expansion into new therapeutic areas
- Increased demand for pharmaceutical products in emerging markets
- Development of personalized medicine
- Leveraging digital health technologies
Threats
- Regulatory changes and pricing pressures
- Competition from other pharmaceutical companies
- Patent expirations
- Economic downturns
Competitive Advantages
- Patented pharmaceutical products provide market exclusivity.
- Strong brand reputation in key therapeutic areas.
- Established relationships with healthcare providers and distributors.
- Extensive research and development capabilities.
About OPHLF
Ono Pharmaceutical Co., Ltd. is a global pharmaceutical company headquartered in Osaka, Japan, with a history stretching back to its founding in 1717. Initially a pharmaceutical wholesaler, the company transitioned to research and development, focusing on innovative drugs. Today, Ono Pharmaceutical develops, manufactures, and markets a wide range of pharmaceutical products and diagnostic reagents across several therapeutic areas, including oncology, diabetes, immunology, and neurology. Key products include Opdivo, an intravenous infusion for malignant tumors, and Glactiv, a tablet for type 2 diabetes. The company also offers treatments for chemotherapy-induced nausea, pheochromocytoma, and other conditions. Ono Pharmaceutical has expanded its global reach through strategic collaborations with companies like Adimab LLC, Turbine Ltd., Sibylla Biotech and academic institutions such as Harvard University. These collaborations enhance its research and development capabilities, allowing it to explore new therapeutic targets and technologies. The company's commitment to innovation and patient care has solidified its position as a key player in the pharmaceutical industry.
What They Do
- Develops and markets pharmaceutical products and diagnostic reagents.
- Offers prescription drugs for oncology, diabetes, immunology, and neurology.
- Conducts research and development to discover new therapeutic targets.
- Manufactures pharmaceutical products in compliance with regulatory standards.
- Collaborates with other companies and research institutions to accelerate drug development.
- Distributes its products globally through a network of distributors and partners.
- Provides patient support programs to improve adherence and outcomes.
Business Model
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Invests in research and development to create new products.
- Partners with other companies to expand its product portfolio and geographic reach.
Industry Context
Ono Pharmaceutical operates within the global pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and high research and development costs. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Ono Pharmaceutical competes with major pharmaceutical companies, including DSRLF (Daiichi Sankyo), FLMNF (Fuji Pharma), GZPHF (Guangzhou Baiyunshan Pharmaceutical), HKMPF (Lee's Pharmaceutical), and HKMPY (Hutchison Medipharma), all vying for market share in key therapeutic areas. The company's focus on innovative therapies and strategic collaborations positions it to capitalize on the growing demand for advanced medical treatments.
Key Customers
- Hospitals and clinics
- Pharmacies
- Patients with various medical conditions
- Healthcare providers
Financials
Chart & Info
Ono Pharmaceutical Co., Ltd. (OPHLF) stock price: Price data unavailable
Latest News
-
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
businesswire.com · Mar 2, 2026
-
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
businesswire.com · Feb 17, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPHLF.
Price Targets
Wall Street price target analysis for OPHLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates OPHLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
OPHLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ono Pharmaceutical may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Lower trading volume and liquidity
- Potential for price manipulation
- Increased regulatory scrutiny
- Higher risk of fraud or mismanagement
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Review the company's investor relations materials and communications.
- Check for any news articles or reports about the company's activities.
- Consult with a financial advisor before investing.
- Established history dating back to 1717
- Global presence and partnerships
- Diverse product portfolio
- Focus on research and development
- Market capitalization of $6.58 billion
Ono Pharmaceutical Co., Ltd. Stock: Key Questions Answered
What does Ono Pharmaceutical Co., Ltd. do?
Ono Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company that discovers, develops, and commercializes innovative medicines to address unmet medical needs. The company's primary focus is on prescription drugs, with a diverse portfolio spanning oncology, diabetes, immunology, and neurology. Ono Pharmaceutical generates revenue through the sale of these pharmaceutical products to hospitals, clinics, pharmacies, and healthcare providers worldwide, with a strong presence in the Japanese market and expanding global reach through strategic partnerships.
What do analysts say about OPHLF stock?
AI analysis is pending for OPHLF stock. Investors should independently research analyst ratings, price targets, and consensus estimates from various financial analysis platforms. Key valuation metrics to consider include the company's P/E ratio, profit margin, and dividend yield. Growth considerations include the company's pipeline of new drugs, expansion into emerging markets, and strategic collaborations. Investors should conduct their own due diligence before making any investment decisions.
What are the main risks for OPHLF?
Ono Pharmaceutical faces several risks inherent to the pharmaceutical industry. These include regulatory risks related to drug approvals and pricing, competition from other pharmaceutical companies, and patent expirations that could lead to generic competition. Additionally, the company faces risks associated with the inherent uncertainties of drug development, including the potential for clinical trial failures and delays. As an OTC-listed stock, OPHLF also faces risks related to lower trading volume and liquidity, as well as increased regulatory scrutiny.
What are the key factors to evaluate for OPHLF?
Ono Pharmaceutical Co., Ltd. (OPHLF) currently holds an AI score of 59/100, indicating moderate score. Key strength: Innovative drug pipeline. Primary risk to monitor: Potential: Regulatory changes and pricing pressures could impact revenue.. This is not financial advice.
How frequently does OPHLF data refresh on this page?
OPHLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven OPHLF's recent stock price performance?
Recent price movement in Ono Pharmaceutical Co., Ltd. (OPHLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative drug pipeline. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider OPHLF overvalued or undervalued right now?
Determining whether Ono Pharmaceutical Co., Ltd. (OPHLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying OPHLF?
Before investing in Ono Pharmaceutical Co., Ltd. (OPHLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited or incomplete.
- AI analysis is pending and will provide further insights.